Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r)
PR Newswire
June 18, 2021 β 10:00 CST
UNLOCK DATA Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech